BACKGROUND: Celiac disease is an immune-mediated enteropathy triggered by gluten in genetically susceptible individuals. Diagnosis is based on evaluating specific autoantibodies and histopathologic findings of duodenal biopsy specimens. The only therapy for celiac disease is a gluten-free diet. Celiac disease can be complicated by malnutrition, other autoimmune diseases, refractoriness to treatment, and gastrointestinal tumors. This article presents seven cases of malignancies in patients with celiac disease. Its objective is to raise awareness of the malignant complications of celiac disease, leading to earlier diagnosis and improved outcomes. CASE PRESENTATION: Seven cases of malignant complications of celiac disease occurred among 190 patients followed at the Department of Internal Medicine and Gastroenterology, University Hospital Brno from 2014 to 2021. We describe these cases and the presentation, diagnostic process, course, management, and outcomes for each, along with proposed potential risk factors of malignant complications. There was one Caucasian man who was 70 years old and six Caucasian women who were 36, 46, 48, 55, 73, and 82 years old in our cohort. Of the seven cases of malignancies in our cohort, four patients were diagnosed with small bowel adenocarcinoma, one with diffuse large B-cell lymphoma, one with carcinoma of the tongue, and one with colorectal carcinoma. CONCLUSIONS: Malignancies occurred in 3.7% of patients followed up for celiac disease. Awareness of the malignant complications of celiac disease, risk factors, presentation, and disease course could lead to earlier diagnosis and improved outcomes.

Department of Internal Medicine 3rd Faculty of Medicine Charles University Prague and Teaching Thomayer Hospital 14059 Prague Czech Republic

Department of Internal Medicine and Gastroenterology University Hospital Brno Faculty of Medicine Masaryk University Jihlavska 20 62500 Brno Czech Republic

Department of Surgery University Hospital Brno Faculty of Medicine Masaryk University 62500 Brno Czech Republic

Zobrazit více v PubMed

van Gils T, Nijeboer P, Overbeek LI, et al. Risks for lymphoma and gastrointestinal carcinoma in patients with newly diagnosed adult-onset celiac disease: consequences for follow-up. United Eur Gastroenterol J. 2018;6(10):1485–1495. doi: 10.1177/2050640618800540. PubMed DOI PMC

Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA. 2002;287(11):1413–1419. doi: 10.1001/jama.287.11.1413. PubMed DOI

Smedby KE. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut. 2005;54(1):54–59. doi: 10.1136/gut.2003.032094. PubMed DOI PMC

Halfdanarson TR, Rubio-Tapia A, Ristow KM, Habermann TM, Murray JA, Inwards DJ. Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma. Clin Gastroenterol Hepatol. 2010;8(12):1042–1047. doi: 10.1016/j.cgh.2010.09.007. PubMed DOI PMC

Green PHR, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy in patients with celiac disease. Am J Med. 2003;115(3):191–195. doi: 10.1016/S0002-9343(03)00302-4. PubMed DOI

Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D. Cancer in patients with ulcerative colitis, Crohn’s disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol. 2008;20(4):297–304. doi: 10.1097/MEG.0b013e3282f2a5e2. PubMed DOI

Askling J, Linet M, Gridley G, Halstensen TS, Ekström K, Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002;123(5):1428–1435. doi: 10.1053/gast.2002.36585. PubMed DOI

Elfström P, Granath F, Ye W, Ludvigsson JF. Low risk of gastrointestinal cancer among patients with celiac disease, inflammation, or latent celiac disease. Clin Gastroenterol Hepatol. 2012;10(1):30–36. doi: 10.1016/j.cgh.2011.06.029. PubMed DOI

Han Y, Chen W, Li P, Ye J. Association between coeliac disease and risk of any malignancy and gastrointestinal malignancy. Medicine (Baltimore) 2015;94(38):e1612. doi: 10.1097/MD.0000000000001612. PubMed DOI PMC

Poyrazoglu OB, Dulger AC. Celiac disease is increased in esophageal squamous cell Carcinoma. Pak J Med Sci. 2021;37(5):1445–1450. doi: 10.12669/pjms.37.5.2757. PubMed DOI PMC

Koskinen I, Hervonen K, Pukkala E, Reunala T, Kaukinen K, Collin P. Cancer incidence and factors associated with malignancies in coeliac disease during long-term follow-up. GastroHep. 2021;3(2):107–115. doi: 10.1002/ygh2.446. DOI

Selby WS, Gallagher ND. Malignancy in a 19-year experience of adult celiac disease. Dig Dis Sci. 1979;24(9):684–688. doi: 10.1007/BF01314465. PubMed DOI

Cottone M, Termini A, Oliva L, et al. Mortality and causes of death in celiac disease in a Mediterranean area. Dig Dis Sci. 1999;44(12):2538–2541. doi: 10.1023/a:1026655609906. PubMed DOI

Collin P, Reunala T, Pukkala E, Laippala P, Keyriläinen O, Pasternack A. Coeliac disease—associated disorders and survival. Gut. 1994;35(9):1215–1218. doi: 10.1136/gut.35.9.1215. PubMed DOI PMC

Al-Toma A, Goerres MS, Meijer JWR, Peña AS, Crusius JBA, Mulder CJJ. Human leukocyte antigen–DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-Cell lymphoma. Clin Gastroenterol Hepatol. 2006;4(3):315–319. doi: 10.1016/j.cgh.2005.12.011. PubMed DOI

Malamut G, Cellier C. Complications of coeliac disease. Best Pract Res Clin Gastroenterol. 2015;29(3):451–458. doi: 10.1016/j.bpg.2015.05.005. PubMed DOI

Goddard CJR, Gillett HR. Complications of coeliac disease: are all patients at risk? Postgrad Med J Lond. 2006;82(973):705–712. doi: 10.1136/pgmj.2006.048876. PubMed DOI PMC

Sieniawski MK, Lennard AL. Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies. Curr Hematol Malig Rep. 2011;6(4):231–240. doi: 10.1007/s11899-011-0097-7. PubMed DOI

Holmes GK, Dunn GI, Cockel R, Brookes VS. Adenocarcinoma of the upper small bowel complicating coeliac disease. Gut. 1980;21(11):1010–1016. doi: 10.1136/gut.21.11.1010. PubMed DOI PMC

Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med. 2013;159(3):169–175. doi: 10.7326/0003-4819-159-3-201308060-00006. PubMed DOI PMC

Lebwohl B, Green PHR, Emilsson L, et al. Cancer risk in 47,241 individuals with celiac disease: a nationwide cohort study. Clin Gastroenterol Hepatol. 2022;20(2):e111–e131. doi: 10.1016/j.cgh.2021.05.034. PubMed DOI

Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet. 2001;358(9279):356–361. doi: 10.1016/s0140-6736(01)05554-4. PubMed DOI

Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in celiac disease. Gastroenterology. 1989;97(2):265–271. doi: 10.1016/0016-5085(89)90060-7. PubMed DOI

Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease–effect of a gluten free diet. Gut. 1989;30(3):333–338. doi: 10.1136/gut.30.3.333. PubMed DOI PMC

Emilsson L, Semrad C, Lebwohl B, Green PHR, Ludvigsson JF. Risk of small bowel adenocarcinoma, adenomas, and carcinoids in a nationwide cohort of individuals with celiac disease. Gastroenterology. 2020;159(5):1686–1694.e2. doi: 10.1053/j.gastro.2020.07.007. PubMed DOI

Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J. 2019;7(5):583–613. doi: 10.1177/2050640619844125. PubMed DOI PMC

Packova B, Kovalcikova P, Pavlovsky Z, et al. Non-invasive prediction of persistent villous atrophy in celiac disease. World J Gastroenterol. 2020;26(26):3780–3791. doi: 10.3748/wjg.v26.i26.3780. PubMed DOI PMC

Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev. 1998;7(3):243–251. PubMed

Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46(2):97–104. doi: 10.1016/j.dld.2013.04.013. PubMed DOI

Howdle PD, Jalal PK, Holmes GKT, Houlston RS. Primary small-bowel malignancy in the UK and its association with coeliac disease. QJM. 2003;96(5):345–353. doi: 10.1093/qjmed/hcg058. PubMed DOI

Zouhairi ME, Venner A, Charabaty A, Pishvaian MJ. Small bowel adenocarcinoma. Curr Treat Options Oncol. 2008;9(4–6):388–399. doi: 10.1007/s11864-009-0098-0. PubMed DOI

Chang H-K, Yu E, Kim J, et al. Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases. Hum Pathol. 2010;41(8):1087–1096. doi: 10.1016/j.humpath.2010.01.006. PubMed DOI

Brousse N, Meijer JWR. Malignant complications of coeliac disease. Best Pract Res Clin Gastroenterol. 2005;19(3):401–412. doi: 10.1016/j.bpg.2005.02.002. PubMed DOI

Marafini I, Monteleone G, Stolfi C. Association between celiac disease and cancer. Int J Mol Sci. 2020;21(11):4155. doi: 10.3390/ijms21114155. PubMed DOI PMC

Locher C, Batumona B, Afchain P, et al. Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO) Dig Liver Dis. 2018;50(1):15–19. doi: 10.1016/j.dld.2017.09.123. PubMed DOI

Giuffrida P, Arpa G, Grillo F, et al. PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. Mod Pathol. 2020;33(7):1398–1409. doi: 10.1038/s41379-020-0497-0. PubMed DOI

Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010;199(6):797–803. doi: 10.1016/j.amjsurg.2009.05.037. PubMed DOI

Vanoli A, Di Sabatino A, Furlan D, et al. Small bowel carcinomas in coeliac or Crohn’s disease: clinico-pathological, molecular, and prognostic features. A study from the small bowel Cancer Italian Consortium. J Crohn’s Colitis. 2017;11(8):942–953. doi: 10.1093/ecco-jcc/jjx031. PubMed DOI

Potter DD, Murray J, Donohue J, et al. The role of defective mismatch repair in small bowel adenocarcinoma in celiac disease. J Am Coll Surg. 2004;199(3):86. doi: 10.1016/j.jamcollsurg.2004.05.187. PubMed DOI

Eells AC, Mackintosh C, Marks L, Marino MJ. Gastroesophageal reflux disease and head and neck cancers: a systematic review and meta-analysis. Am J Otolaryngol. 2020;41(6):102653. doi: 10.1016/j.amjoto.2020.102653. PubMed DOI

Langevin SM, Michaud DS, Marsit CJ, et al. Gastric reflux is an independent risk factor for laryngopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1061–1068. doi: 10.1158/1055-9965.EPI-13-0183. PubMed DOI PMC

Lebwohl B, Stavsky E, Neugut AI, Green PHR. Risk of colorectal adenomas in patients with celiac disease. Aliment Pharmacol Ther. 2010;32(8):1037–1043. doi: 10.1111/j.1365-2036.2010.04440.x. PubMed DOI PMC

Pereyra L, Gonzalez R, Mohaidle A, et al. Risk of colorectal neoplasia in patients with celiac disease: a multicenter study. J Crohn’s Colitis. 2013;7(12):e672–e677. doi: 10.1016/j.crohns.2013.06.005. PubMed DOI

Volta U, Vincentini O, Quintarelli F, Felli C, Silano M, Caio G. Collaborating Centres of the Italian Registry of the Complications of Celiac Disease. Low risk of colon cancer in patients with celiac disease. Scand J Gastroenterol. 2014;49:564–568. doi: 10.3109/00365521.2014.893012. PubMed DOI

DiffuseLargeBCellLymphoma.pdf - DIFFUSE LARGE B-CELL LYMPHOMA Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of | Course Hero. https://www.who.int/selection_medicines/committees/expert/20/applications/DiffuseLargeBCellLymphoma.pdf?ua=1&ua=1. Accessed 26 Jan 2022.

Nijeboer P, van Wanrooij R, van Gils T, et al. Lymphoma development and survival in refractory coeliac disease type II: histological response as prognostic factor. United Eur Gastroenterol J. 2017;5(2):208–217. doi: 10.1177/2050640616646529. PubMed DOI PMC

Mearin M, Catassi C, Brousse N, et al. European multi-centre study on coeliac disease and non-Hodgkin lymphoma. Eur J Gastroenterol Hepatol. 2006;18:187–194. doi: 10.1097/00042737-200602000-00012. PubMed DOI

Al-Toma A, Verbeek WHM, Hadithi M, von Blomberg BME, Mulder CJJ. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut. 2007;56(10):1373–1378. doi: 10.1136/gut.2006.114512. PubMed DOI PMC

Di Sabatino A, Biagi F, Gobbi PG, Corazza GR. How I treat enteropathy-associated T-cell lymphoma. Blood. 2012;119(11):2458–2468. doi: 10.1182/blood-2011-10-385559. PubMed DOI

Chan JKC, Chan ACL, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35(10):1557–1569. doi: 10.1097/PAS.0b013e318222dfcd. PubMed DOI

Eigner W, Bashir K, Primas C, et al. Dynamics of occurrence of refractory coeliac disease and associated complications over 25 years. Aliment Pharmacol Ther. 2017;45(2):364–372. doi: 10.1111/apt.13867. PubMed DOI

Arps DP, Smith LB. Classic versus type II enteropathy-associated T-cell lymphoma: diagnostic considerations. Arch Pathol Lab Med. 2013;137(9):1227–1231. doi: 10.5858/arpa.2013-0242-CR. PubMed DOI

Al-Toma A, Verbeek WHM, Visser OJ, et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis. 2007;39(7):634–641. doi: 10.1016/j.dld.2007.03.009. PubMed DOI